Bone Biologics Corp
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
BBLG$0.33+3.0%Stored close · as of Nov 6, 2026
Contents
Consolidated Statements of Operations
| Year Ended December 31, 2025 | Year Ended December 31, 2024 | |
|---|---|---|
| Revenues · $ · - · $ · - | ||
| Operating expenses | ||
| Research and development | 1,060,191 | 2,130,385 |
| General and administrative | 2,174,751 | 2,088,776 |
| Total operating expenses | 3,234,942 | 4,219,161 |
| Loss from operations | (3,234,942) | (4,219,161) |
| Other income | ||
| Change in fair value of warrant liability | 3,967 | 51,081 |
| Interest income | 121,984 | 55,660 |
| Total other income | 125,951 | 106,741 |
| Net loss | (3,108,991) | (4,112,420) |
| Deemed dividend on warrant inducements | - | (3,212,504) |
| Net loss attributable to common stockholders | $(3,108,991) | $(7,324,924) |
| Weighted average shares of common outstanding – basic and diluted(1) | 1,174,869 | 252,960 |
| Loss per share – attributable to common stockholders, basic and diluted(1) | $(2.65) | $(28.96) |
| (1) | Adjusted to reflect the reverse stock split as described in Note 1. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.